Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30(5) of the SEBI (LODR) Regulations 2015
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has filed a routine disclosure with NSE under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulation 30(5). This regulation requires a listed company to inform the stock exchange about the names of its Key Managerial Personnel (KMPs) or other authorized officers who will be responsible for deciding whether an event or piece of information is 'material' enough to be disclosed to the public. In short, the company is naming the people authorized to make materiality decisions for future corporate disclosures. No specific business event, financial numbers, or strategic decision is part of this filing.
This is a routine corporate governance compliance filing with no impact on the company's financials, operations, or stock price. It does not signal any new business development, earnings update, or material event for shareholders.